AshEse Journal of Pharmacy
The AshEse Journal of Pharmacy (AJP) is an international journal which provides rapid publication (monthly) of research papers, review papers, review articles, mini review and short communications in all aspects of Pharmaceutical sciences which include pharmacy and pharmaceutical sciences (Pharmaceutical Technology, Pharmacognosy, Natural Product Research, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Medicinal plants, Computational Chemistry and Molecular Drug Design, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics, Pharmacoeconomics). The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance.
AshEse Journal of Pharmacy welcomes the submission of the following types of manuscripts:
Regular articles: These should describe new and carefully confirmed findings, and research methods should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.
Short Communications: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models, innovative methods or techniques. The style of main sections need not conform to that of full-length papers.
Reviews: Should provide a comprehensive and scholarly account of a topic that has direct relevance to Pharmacitical field and that has not recently been covered in the literature. Normally these are authored by individuals who have themselves made a significant contribution to the original literature on the topic under review and are acknowledged authorities in the field.
All papers submitted to AshEse Journal of Pharmacy are seen by one or more members of the Editorial Board. At this stage, some are rejected without peer review owing to lack of novelty, involvement of normal subjects, serious scientific flaws or work lying outside the scope of the journal. Suitable articles are sent to at least two experts for review, whose reports are returned to the assigned member of the Editorial Board and the Editor. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review. Following peer review, we recommend articles for revision by authors, based on reviewers’ reports prior to publication. Revision of an article gives no guarantee of acceptance and in some cases revised articles are rejected if the improvements are not sufficient or new issues arise. Material submitted to AshEse Journal of Pharmacy remains confidential while under review and peer reviewers’ identities are protected, unless they elect to lose anonymity.
AshEse has specific style criteria and using these in preparing your manuscript will speed up the production process should your article be accepted for publication. Manuscripts should be double-spaced, including text, tables, legends and references. The main text should be saved as a DOC or MS file. PDF files are not acceptable. Please do not prepare your manuscript as a LaTeX file, as these do not convert correctly for review.
(i) Full title of the paper (maximum of 100 characters). Please note we do not allow any abbreviations in titles except for current accepted gene symbols.
(ii) Author names and affiliations.
(iii) Full postal and e-mail address of the corresponding author.
Please include an abstract containing up to but not more than 250 words. The abstract must summarize the paper in full, including background, methods, results and conclusion, although these subtitles should not be included. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Details such as the number of subjects, number of controls, the age range of patients and their gender should be included. Statistical evidence to support your main conclusions should also be included here. Abbreviations or reference citations should not appear in the abstract, except for current accepted gene symbols.
Keywords of the authors’ choice up to a maximum of five should be provided below the abstract.
Aim to make your paper reader-friendly to those outside your field by avoiding all abbreviations where possible. The Scientific Editor reserves the right to replace abbreviations with their full meaning. Do not abbreviate the name of a disease unless it is unwieldy and complicated: Parkinson's disease, Alzheimer's disease, multiple sclerosis and Huntington’s disease etc to mention a few. Abbreviations, if they must appear, should be written in full in the abstract section.
The numbers one to nine are written in full, unless followed by a unit, e.g. five mice, 6 days, seven patients with Parkinson’s disease, 8 ml.
Sections should include, in order:
Introduction: should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of disciplines.
Materials and methods: Materials and Methods should start as a continuation to the introduction of the same page. All important materials used along with their source shall be mentioned. The main methods used shall be briefly described with appropriate reference. New methods or substantially modified methods may be described in sufficient detail. Methods in general use need not be described in detail. The statistical method and the level of significance chosen shall be clearly stated.
Results: should be presented with clarity and precision. The results should be written in the past tense when describing author's findings. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.
Discussion: Discussion section should follow results, deal with the interpretation of results, convey how they help to increase the current understanding of the problem and should be logical. Unsupported hypothesis should be avoided. The Discussion should state the possibilities the results uncover, that need to be further explored. The Results and Discussion sections when appropriate can be combined as Results and Discussion.
Conclusions: A brief Conclusions section is desirable, but not essential. It must be followed by one empty line.
Acknowledgements: Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements. Please list the source(s) of funding for the study, for each author, and for the manuscript preparation in the acknowledgements section. Please acknowledge anyone who contributed towards the study by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Also include their source(s) of funding, acknowledge anyone who contributed materials vital for the study.
Tables: should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the research methods should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.
Figure legends: should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or PowerPoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.
References: In the text, a reference identified by means of an author’s name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author’s name should be mentioned, followed by ‘et al’. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like ‘a’ and ‘b’ after the date to distinguish the works.
Abanum (2014), Agindotan et al. (2010), (Kelebeni, 1983), (Usman and Smith, 1992), (Chege, 1998; Chukwura, 1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001).
References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.
Format: Author(s) of article (surname initials) (Year of publication). Title of article. Journal title abbreviated. volume number (issue number):page numbers.
Chikere CB, Omoni VT and Chikere BO (2008). Distribution of potential nosocomial pathogens in a hospital environment. Afr. J. Biotechnol. 7: 3535-3539.
Moran GJ, Amii RN, Abrahamian FM, Talan DA (2005). Methicillin resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11: 928-930.
Books and other monographs
Format: Author(s) of book (surname initials) (Year of publication). Title of book. Edition. Publisher: Place of publication. Page numbers
Ebling FJ, Cunliffe WJ (1992). Disorders of sebaceous glands. In: Rook A, Wilkinson DS, Ebling FJ, Champion RH, Burton JL, Eds. Textbook of dermatology. Vol III. Blackwell Scientific: Boston. 1699-744.
Electronic journal article/World Wide Web
Format: Author/editor (surname initials) (Year). "Title" [online]. Available from: URL: World Wide Web page
Blanc F, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E (2011). Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365: 1471-1481. Available from:http://www.nejm.org/doi/full/10.1056/NEJMoa1013911. Accessed 2012, January 20.
Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage. Because (AJP) will be published online without access restrictions, authors will have electronic access to the full text (PDF) of the article. Authors can download the PDF file from which they can print unlimited copies of their articles.
Copyright: Submission of a manuscript implies that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.